Skip to main content

Fiscal Wizard · Single-issue tearsheet

XAIR / Jun 21, 2026 Run #7321

XAIR

Beyond Air, Inc.

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Composite verdict

F 13.2 / 100
Bearish setup · Reversal 14 drivers · 7 gates blocking
  • Rate of Change
  • Pin Bar
  • ADX DI Cross
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 101st of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 1Mean-reversion Neutral 49
  • Late-stage trendTrend signals have been live for 98 bars — past the ~60-bar window; momentum edge decays and can reverse late in a move. (medium confidence)
Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

26.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Greenblatt EY 0
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
EV/Sales 75
FCF Margin 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Rate of Change, Pin Bar, ADX DI Cross); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 7
MACD Signal Cross 15
Pin Bar 16

Risk Gates

7 blocking 6 caution

7 guards active, 18 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Debt-to-Assets Blocking

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

LT Debt-to-Equity Blocking

High long-term D/E blocks bullish signals — structural-leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for XAIR.